POM-V Prescription Required

RenuTend Suspension for Injection for Horses

Active ingredient: Tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells (tpMSCs)

Form

Injection

Species

Horses

Manufacturer

Boehringer Ingelheim Vetmedica GmbH

VMD MA No.

04491/5064

What it's used for

To restore fibre alignment in horses with superficial digital flexor tendon or suspensory ligament fibre disruption

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Tenogenic primed equine allo...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

RenuTend Suspension for Injection for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

To restore fibre alignment in horses with superficial digital flexor tendon or
suspensory ligament fibre disruption

Route of administration:
Intra-lesional use.
Dosage:
A single intra-lesional injection of 1 ml per animal on one occasion.
Preparation of the suspension for injection:
The veterinary medicinal product must be administered intra-lesionally by a licensed
veterinarian taking special precautions to ensure sterility of the injection process. The
veterinary medicinal product should be handled and injected using sterile techniques
and in a clean environment.
The veterinary medicinal product is required to be administered immediately after
thawing in order to maintain cell viability.
Using appropriate gloves, remove the vial from the freezer/liquid nitrogen and thaw
immediately at 25 °C–37 °C, e.g. in a water bath, until the content is completely
thawed (approximately 5 minutes).
If any cell clusters are visible after thawing, gently invert the vial until the suspension
is clear and colourless.
Remove the cap of the vial and aspirate the suspension into a sterile syringe for
injection.
Administer using a needle with a diameter greater than or equal to 22G in order to
prevent cell damage.

Amended pages: May 2022
AN: 01366/2020
Administer intra-lesionally under ultrasound guidance with chemical or physical
restraint as needed according to good veterinary practice to facilitate a safe intra-
lesional injection. After insertion of the needle into the tendon or ligament, redirect
the needle, if necessary, until the lesion is reached. Slowly inject the suspension. In
case of a larger lesion the needle can be slowly retracted during injection to facilitate
dispersion of the cells throughout the lesion.

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not administer simultaneously with any other intra-lesional veterinary medicinal
product

Mild injection site reactions, such as increased heat, pain at palpation, limb swelling
and increased limb circumference occurred very commonly during the first 10 days
after administration.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

The veterinary medicinal product has been demonstrated to be efficacious in horses
with first time overstrain lesions in the superficial digital flexor tendon of the front leg,
or the suspensory ligament in the back or front leg. Efficacy data are not available
regarding treatment of other tendons and ligaments. Treatment of traumatic injuries
with lacerations or completely ruptured tendons has not been evaluated. This
veterinary medicinal product is not intended for treatment of such injuries.

Amended pages: May 2022
AN: 01366/2020
The efficacy of the veterinary medicinal product was demonstrated in a pivotal field
trial with horses working at training level or competition level within the disciplines
dressage or show jumping, before tendon or ligament injury occurred. By day 112
post-treatment, 65% of horses treated with this product during the pivotal field trial
had achieved greater than 75% fibre alignment within the affected soft tissues.
A standard program of box rest and slowly increasing exercise regimen under
veterinary guidance is required as part of the rehabilitation of tendon and ligament
injuries. The program should be adapted based on serial ultrasonographic monitoring
and clinical signs such as lameness, heat and swelling.
The efficacy and safety of the veterinary medicinal product were demonstrated in a
pivotal field trial after single administration of the veterinary medicinal product and
concurrent single systemic administration of an NSAID (ketoprofen or meloxicam).
According to the benefit-risk assessment of the responsible veterinarian of the
individual case a single dose systemic NSAID may be administered on the day of
intra-lesional injection.

Special precautions for use in animals
A correct foot balance is critical in the management of superficial digital flexor tendon
or suspensory ligament lesions.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
When the veterinary medicinal product is stored in liquid nitrogen, direct exposure to
liquid nitrogen or cold nitrogen vapours can cause extensive tissue damage or burns.
When liquid nitrogen vaporises, it can expand to 700-times its volume which may
create an explosion hazard in unvented cryovials. Liquid nitrogen containers should be
handled by properly trained personnel only. The handling of liquid nitrogen should take
place in a well-ventilated area. Before withdrawing the vials from the liquid nitrogen
canister, protective equipment consisting of gloves, long sleeves and a facemask or
goggles should be worn.
There is only limited data available to support the human safety of this product. In
particular, women of childbearing age and people with compromised immune systems
should take care to avoid contact with the product. It is recommended to wear
impermeable gloves at all times whilst handling and administering the product. Wash
any spills off exposed skin, eyes, or mucous membranes immediately.
Take care not to accidentally self-administer this product. In case of accidental self-
injection, this veterinary medicinal product can cause pain, local inflammatory
reactions and swelling at the site of injection, which may persist for several weeks.
Transient fever may also occur. Seek medical advice immediately and provide the
package leaflet or label to the physician.

Amended pages: May 2022
AN: 01366/2020

Do not administer simultaneously with any other intra-lesional veterinary medicinal
product.’

Meat and Offal: zero days
Milk: zero hours
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.